Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARBUTUS BIOPHARMA CORPORATION

(ABUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Holding Up After Market Reversal Wednesday

12/01/2021 | 04:03pm EST


© MT Newswires 2021
All news about ARBUTUS BIOPHARMA CORPORATION
01/24ARBUTUS BIOPHARMA : Corporate Presentation - January 2022
PU
01/24ARBUTUS BIOPHARMA : Announces 2022 Corporate Objectives and Provides Financial Update - Fo..
PU
01/24ARBUTUS BIOPHARMA CORP : Results of Operations and Financial Condition, Other Events, Fina..
AQ
01/24Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
GL
01/24Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
GL
01/04Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
GL
2021Roivant Sciences Up 28%, Continuing Increase
DJ
2021MODERNATX, INC. V. ARBUTUS BIOPHARMA : Sublicense Not Enough To Show Standing
AQ
2021Patent Case Summaries | Week Ending December 3, 2021
AQ
2021Arbutus, Antios Dose First Patient in Phase 2a Trial with AB-729, ATI-2173 for Hepatiti..
MT
More news
Analyst Recommendations on ARBUTUS BIOPHARMA CORPORATION
More recommendations
Financials
Sales 2021 13,5 M 10,6 M 10,6 M
Net income 2021 -106 M -82,7 M -82,7 M
Net Debt 2021 - - -
P/E ratio 2021 -2,82x
Yield 2021 -
Capitalization 417 M 327 M 327 M
Capi. / Sales 2021 30,9x
Capi. / Sales 2022 23,8x
Nbr of Employees 77
Free-Float 69,2%
Chart ARBUTUS BIOPHARMA CORPORATION
Duration : Period :
Arbutus Biopharma Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARBUTUS BIOPHARMA CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 3,08 CAD
Average target price 8,03 CAD
Spread / Average Target 160%
EPS Revisions
Managers and Directors
William H. Collier President, Chief Executive Officer & Director
David C. Hastings Chief Financial & Accounting Officer
Frank M. Torti Chairman
Michael J. Sofia Chief Scientific Officer
Elizabeth Howard Secretary, Chief Compliance Officer & EVP
Sector and Competitors
1st jan.Capi. (M$)
ARBUTUS BIOPHARMA CORPORATION-37.79%327
CSL LIMITED-14.20%84 148
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 757
ALEXION PHARMACEUTICALS, INC.0.00%40 336
SAMSUNG BIOLOGICS CO.,LTD.-21.15%39 159
BIOGEN INC.-8.74%32 161